Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Y Kim

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Cell|October 24, 2006
The regulation of INK4/ARF in cancer and agingWilliam Y Kim, Norman E Sharpless
Cancer Cell|April 9, 2008
VHL inactivation: a new road to senescenceWilliam Y Kim, Norman E Sharpless
Cancer Discovery|August 3, 2017
<i>Bap1</i> and <i>Pbrm1:</i> Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell CarcinomaJanet Y Leung, William Y Kim
Seminars in Oncology|October 19, 2006
Molecular pathways in renal cell carcinoma--rationale for targeted treatmentWilliam Y Kim, William G Kaelin
Current Topics in Microbiology and Immunology|August 9, 2011
Drug efficacy testing in miceWilliam Y Kim, Norman E Sharpless
Biomaterials|February 6, 2013
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapyYuan Zhang, William Y Kim, Leaf Huang
Expert Opinion on Therapeutic Targets|September 22, 2010
HIF, hypoxia and the role of angiogenesis in non-small cell lung cancerAutumn L Jackson, Bing Zhou, William Y Kim
Cell Reports. Medicine|May 18, 2022
A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade responseWilliam H Weir, Peter J Mucha, William Y Kim
Expert Review of Anticancer Therapy|February 19, 2008
mTOR pathway in renal cell carcinomaSara C Hanna, Samuel A Heathcote, William Y Kim
American Journal of Cancer Research|October 6, 2017
Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies <i>GRIA1</i> as a prognostic biomarker for basal-like bladder cancerSloane K Tilley, William Y Kim, Rebecca C Fry
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Cell|October 24, 2006
The regulation of INK4/ARF in cancer and agingWilliam Y Kim, Norman E Sharpless
Cancer Cell|April 9, 2008
VHL inactivation: a new road to senescenceWilliam Y Kim, Norman E Sharpless
Cancer Discovery|August 3, 2017
<i>Bap1</i> and <i>Pbrm1:</i> Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell CarcinomaJanet Y Leung, William Y Kim
Seminars in Oncology|October 19, 2006
Molecular pathways in renal cell carcinoma--rationale for targeted treatmentWilliam Y Kim, William G Kaelin
Current Topics in Microbiology and Immunology|August 9, 2011
Drug efficacy testing in miceWilliam Y Kim, Norman E Sharpless
Biomaterials|February 6, 2013
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapyYuan Zhang, William Y Kim, Leaf Huang
Expert Opinion on Therapeutic Targets|September 22, 2010
HIF, hypoxia and the role of angiogenesis in non-small cell lung cancerAutumn L Jackson, Bing Zhou, William Y Kim
Cell Reports. Medicine|May 18, 2022
A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade responseWilliam H Weir, Peter J Mucha, William Y Kim
Expert Review of Anticancer Therapy|February 19, 2008
mTOR pathway in renal cell carcinomaSara C Hanna, Samuel A Heathcote, William Y Kim
American Journal of Cancer Research|October 6, 2017
Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies <i>GRIA1</i> as a prognostic biomarker for basal-like bladder cancerSloane K Tilley, William Y Kim, Rebecca C Fry
Pageof 14